Personalis Net Profit Margin 2018-2025 | PSNL
Personalis net profit margin from 2018 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.
| Personalis Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2025-03-31 |
$0.09B |
$-0.08B |
-96.55% |
| 2024-12-31 |
$0.09B |
$-0.08B |
-94.19% |
| 2024-09-30 |
$0.09B |
$-0.09B |
-103.37% |
| 2024-06-30 |
$0.08B |
$-0.08B |
-101.23% |
| 2024-03-31 |
$0.08B |
$-0.09B |
-124.00% |
| 2023-12-31 |
$0.07B |
$-0.11B |
-147.30% |
| 2023-09-30 |
$0.07B |
$-0.11B |
-159.15% |
| 2023-06-30 |
$0.07B |
$-0.11B |
-161.76% |
| 2023-03-31 |
$0.07B |
$-0.11B |
-165.22% |
| 2022-12-31 |
$0.07B |
$-0.11B |
-173.85% |
| 2022-09-30 |
$0.07B |
$-0.10B |
-147.83% |
| 2022-06-30 |
$0.08B |
$-0.09B |
-123.68% |
| 2022-03-31 |
$0.08B |
$-0.08B |
-101.25% |
| 2021-12-31 |
$0.09B |
$-0.07B |
-75.58% |
| 2021-09-30 |
$0.09B |
$-0.06B |
-68.24% |
| 2021-06-30 |
$0.08B |
$-0.05B |
-60.24% |
| 2021-03-31 |
$0.08B |
$-0.04B |
-55.00% |
| 2020-12-31 |
$0.08B |
$-0.04B |
-52.56% |
| 2020-09-30 |
$0.08B |
$-0.04B |
-46.05% |
| 2020-06-30 |
$0.07B |
$-0.03B |
-43.84% |
| 2020-03-31 |
$0.07B |
$-0.03B |
-41.43% |
| 2019-12-31 |
$0.07B |
$-0.03B |
-40.00% |
| 2019-06-30 |
$0.04B |
$-0.02B |
-38.10% |
| 2019-03-31 |
$0.04B |
$-0.02B |
-48.57% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.550B |
$0.085B |
|
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
|
